Jiali Nie1,2, Quanlu Duan1,2, Mengying He1,2, Xianqing Li1,2, Bei Wang1,2, Chi Zhou1,2, Lujin Wu1,2, Zheng Wen1,2, Chen Chen1,2, Dao Wu Wang3, Katherina M Alsina4, Xander H T Wehrens4, Dao Wen Wang1,2, Li Ni1,2,4. 1. Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China. 3. Department of Cardiology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China. 4. Department of Molecular Physiology & Biophysics and Department of Medicine, Cardiovascular Research Institute, Cardiology Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: Cardiac hypertrophy and heart failure are characterized by increased late sodium current and abnormal Ca2+ handling. Ranolazine, a selective inhibitor of the late sodium current, can reduce sodium accumulation and Ca 2+ overload. In this study, we investigated the effects of ranolazine on pressure overload-induced cardiac hypertrophy and heart failure in mice. METHODS AND RESULTS: Inhibition of late sodium current with the selective inhibitor ranolazine suppressed cardiac hypertrophy and fibrosis and improved heart function assessed by echocardiography, hemodynamics, and histological analysis in mice exposed to chronic pressure overload induced by transverse aortic constriction (TAC). Ca2+ imaging of ventricular myocytes from TAC mice revealed both abnormal SR Ca 2+ release and increased SR Ca 2+ leak. Ranolazine restored aberrant SR Ca 2+ handling induced by pressure overload. Ranolazine also suppressed Na + overload induced in the failing heart, and restored Na + -induced Ca 2+ overload in an sodium-calcium exchanger (NCX)-dependent manner. Ranolazine suppressed the Ca 2+ -dependent calmodulin (CaM)/CaMKII/myocyte enhancer factor-2 (MEF2) and CaM/CaMKII/calcineurin/nuclear factor of activated T-cells (NFAT) hypertrophy signaling pathways triggered by pressure overload. Pressure overload also prolonged endoplasmic reticulum (ER) stress leading to ER-initiated apoptosis, while inhibition of late sodium current or NCX relieved ER stress and ER-initiated cardiomyocyte apoptosis. CONCLUSIONS: Our study demonstrates that inhibition of late sodium current with ranolazine improves pressure overload-induced cardiac hypertrophy and systolic and diastolic function by restoring Na+ and Ca 2+ handling, inhibiting the downstream hypertrophic pathways and ER stress. Inhibition of late sodium current may provide a new treatment strategy for cardiac hypertrophy and heart failure.
BACKGROUND:Cardiac hypertrophy and heart failure are characterized by increased late sodium current and abnormal Ca2+ handling. Ranolazine, a selective inhibitor of the late sodium current, can reduce sodium accumulation and Ca 2+ overload. In this study, we investigated the effects of ranolazine on pressure overload-induced cardiac hypertrophy and heart failure in mice. METHODS AND RESULTS: Inhibition of late sodium current with the selective inhibitor ranolazine suppressed cardiac hypertrophy and fibrosis and improved heart function assessed by echocardiography, hemodynamics, and histological analysis in mice exposed to chronic pressure overload induced by transverse aortic constriction (TAC). Ca2+ imaging of ventricular myocytes from TACmice revealed both abnormal SRCa 2+ release and increased SRCa 2+ leak. Ranolazine restored aberrant SRCa 2+ handling induced by pressure overload. Ranolazine also suppressed Na + overload induced in the failing heart, and restored Na + -induced Ca 2+ overload in an sodium-calcium exchanger (NCX)-dependent manner. Ranolazine suppressed the Ca 2+ -dependent calmodulin (CaM)/CaMKII/myocyte enhancer factor-2 (MEF2) and CaM/CaMKII/calcineurin/nuclear factor of activated T-cells (NFAT) hypertrophy signaling pathways triggered by pressure overload. Pressure overload also prolonged endoplasmic reticulum (ER) stress leading to ER-initiated apoptosis, while inhibition of late sodium current or NCX relieved ER stress and ER-initiated cardiomyocyte apoptosis. CONCLUSIONS: Our study demonstrates that inhibition of late sodium current with ranolazine improves pressure overload-induced cardiac hypertrophy and systolic and diastolic function by restoring Na+ and Ca 2+ handling, inhibiting the downstream hypertrophic pathways and ER stress. Inhibition of late sodium current may provide a new treatment strategy for cardiac hypertrophy and heart failure.
Authors: Antonis A Armoundas; Ion A Hobai; Gordon F Tomaselli; Raimond L Winslow; Brian O'Rourke Journal: Circ Res Date: 2003-06-12 Impact factor: 17.367
Authors: Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass Journal: Nat Med Date: 2005-01-23 Impact factor: 53.440
Authors: Koenraad Philippaert; Subha Kalyaanamoorthy; Mohammad Fatehi; Wentong Long; Shubham Soni; Nikole J Byrne; Amy Barr; Jyoti Singh; Jordan Wong; Taylor Palechuk; Chloe Schneider; Ahmed M Darwesh; Zaid H Maayah; John M Seubert; Khaled Barakat; Jason R B Dyck; Peter E Light Journal: Circulation Date: 2021-04-09 Impact factor: 29.690
Authors: Alessandro Bertero; Paul A Fields; Alec S T Smith; Andrea Leonard; Kevin Beussman; Nathan J Sniadecki; Deok-Ho Kim; Hung-Fat Tse; Lil Pabon; Jay Shendure; William S Noble; Charles E Murry Journal: J Cell Biol Date: 2019-08-08 Impact factor: 10.539